MedTrace Logo

Urokinase Therapy in Patients With Diabetic Foot Syndrome

NCT00823225 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-03-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether the additional therapy with low dose urokinase is more effective than only a conventional standard therapy concerning ulcer-healing, rate of major amputation and survival.

Conditions

  • Diabetic Foot
  • Arterial Occlusive Disease
  • Ischemia

Interventions

PROCEDURE

standard therapy

wound debridement, moist wound dressing

DRUG

Urokinase

Daily infusion up to 21 applications, dose dependent on fibrinogen level: \> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU

Sponsors & Collaborators

  • medac GmbH

    lead INDUSTRY

Principal Investigators

  • Sebastian Schellong, MD · Krankenhaus Dresden-Friedrichstadt, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823225 on ClinicalTrials.gov